SpringerLink
Log in

Hyperthermia and Intracavitary Chemotherapy in Prevention and Treatment of Malignant Effusions

  • Chapter
  • First Online:
Malignant Effusions

Abstract

Primitive or metastatic Pleura and peritoneal tumors are not easy treatable disease state. Intravenous systemic chemotherapy and surgery when possible are the first approaches. However, both treatment can be ameliorated and peculiarly chemotherapy. After, Dedrick and Markman studies on ovarian tumors in the late 1960 the direct intra-peritoneal (IP) instillation of anticancer agents compared to systemic therapy IP chemotherapy has shown pharmacological advantages. The increased local concentration of drugs obtained by IP instillation has improved the prognosis in patients with peritoneal carcinosis, but the response rate and the chemotherapy resistance could further ameliorate by combining surgery, chemotherapy and hyperthermia. In this brief overview, the reasons for adding or using IP chemotherapy plus hyperthermia, post surgical removal of tumor masses, and devices for obtaining these results are described.

In fond memory of our good friend and teacher Dieter E Hager, Dr. med. rer. nat. Dipl, -Phis, Director of BioMed- Klinik, Bad Bergzabern, Germany. * 15.01.1947 † 13.12.2009.

“All therapeutic interdisciplinary regimens are acceptable if they do not become laws, and if those who violate them do not become ipso facto criminals” N. Delepine 2010

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (Brazil)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (Brazil)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (Brazil)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (Brazil)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198:999–1011

    PubMed  Google Scholar 

  2. American Thoracic Society (2000) Management of malignant pleural effusions. Am J Resp Care Med 162:1987–2001

    Google Scholar 

  3. Amini A, Masoumi Moghaddam S, Morris DL, Pourgholami MH (2012) Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J Oncol 2012:540791

    PubMed  Google Scholar 

  4. Ammouri L, Prommer EE (2010) Palliative treatment of malignant ascites: profile of catumaxomab. Biologics 4:103–110

    PubMed  CAS  Google Scholar 

  5. Armstrong DK, Bundy B, Wenzel L (2006) Gynecologic oncology group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    PubMed  CAS  Google Scholar 

  6. Astoul PH, Viallat JR, Laurent JC et al (1993) Intrapleural recombinant Il-2 in passive immunotherapy for malignant pleural effusion. Chest 103:209–213

    PubMed  CAS  Google Scholar 

  7. Ba MC, Cui SZ, Lin SQ et al (2010) Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol 16:1901–1977

    PubMed  CAS  Google Scholar 

  8. Bazzoni G, Dejana E (2001) Pores in the sieve and channels in the wall: control of paracellular permeability by junctional proteins in endothelial cells. Microcirculation 8:143–152

    PubMed  CAS  Google Scholar 

  9. Bogliolo GV, Lerza R, Bottino GB (1991) Regional pharmacokinetic selectivity of intrapleural cisplatin. Eur J Cancer 27:839–842

    PubMed  CAS  Google Scholar 

  10. Bonomo L, Feragalli B, Sacco R et al (2000) Malignant pleural disease. Eur J Radiol 34:98–118

    PubMed  CAS  Google Scholar 

  11. Butchart EG (1999) Contemporary management of malignant pleural mesothelioma. Oncologist 4:488–500

    PubMed  CAS  Google Scholar 

  12. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186

    PubMed  CAS  Google Scholar 

  13. Cao C, Yan TD, Black D, Morris DL (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16:2152–2165

    PubMed  Google Scholar 

  14. Ceelen WP, Flessner MF (2010) Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 7:108–115

    PubMed  Google Scholar 

  15. Chaudhary K, Haddadin S, Nistala R, Papageorgio C (2010) Intraperitoneal drug therapy: an advantage. Curr Clin Pharmacol 5:82–88

    PubMed  CAS  Google Scholar 

  16. Chung M, Kozuch P (2008) Treatment of malignant ascites. Curr Treat Options Oncol 9:215–233

    PubMed  Google Scholar 

  17. Clifford CA, Hughes D, Beal MW et al (2002) Vascular endothelial growth factor concentrations in body cavity effusions in dogs. J Vet Intern Med 16:164–168

    PubMed  Google Scholar 

  18. Collins JM (1984) Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498–504

    PubMed  CAS  Google Scholar 

  19. Dahlke MH, Schlitt HJ, Piso P (2007) Continuous peritoneal perfusion: techniques, methods and applications. In: Ceelen WP (ed) Peritoneal carcinomatosis. A multidisciplinary approach. Springer Science Business Media

    Google Scholar 

  20. Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12:1–6

    PubMed  CAS  Google Scholar 

  21. Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89:480–487

    PubMed  CAS  Google Scholar 

  22. De Simone M, Aimone M, Izzo G et al (1997) Peritonectomy and hyperthermic antiblastic peritoneal perfusion (HAT) for peritoneal carcinomatosis. J Exp Clin Cancer Res 16:356–357

    Google Scholar 

  23. Deraco M, Kusamura S, Virzì S et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol 122:215–220

    PubMed  Google Scholar 

  24. Dogramatzis D, Nishikawa K, Newman RA (1991) Interaction of hyperthermia with bleomycin and liblomycin: effects on CHO cells in vitro. Anticancer Res 11:1359–1364

    PubMed  CAS  Google Scholar 

  25. Elit L, Oliver TK, Covens A (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 109:692–702

    PubMed  CAS  Google Scholar 

  26. Facchiano E, Scaringi S, Kianmanesh R et al (2008) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 34:154–158

    PubMed  CAS  Google Scholar 

  27. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136–151

    PubMed  CAS  Google Scholar 

  28. Flessner MF (2007) Intraperitoneal drug therapy: physical and biological principles. In: Ceelen WP (ed) Peritoneal carcinomatosis. A multidisciplinary approach. Springer, New York

    Google Scholar 

  29. Frei E, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69:585–504

    PubMed  Google Scholar 

  30. Fuhrer G, Lazarus AA (2011) Mesothelioma. Dis Mon 57:40–54

    PubMed  Google Scholar 

  31. Fujimoto S, Takahashi M, Okui K (1991) A prospective study on combined treatment of intraperitoneal hyperthermic and surgery for patients with refractory gastric cancer. In: Taguchi T, Aigner KR (eds) Mitomycin C in cancer chemotherapy today. Excerpta Medica, Tokyo

    Google Scholar 

  32. Fujimoto S, Takahashi M, Mutou T et al (1999) Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 85:529–534

    PubMed  CAS  Google Scholar 

  33. Fujimura T, Yonemura Y, Fushida S et al (1990) Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 65:65–71

    PubMed  CAS  Google Scholar 

  34. Fujiwara K, Markman M, Morgan M, Coleman RL (2005) Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 97:10–15

    PubMed  CAS  Google Scholar 

  35. Garofalo A, Valle M, Garcia J, Sugarbaker PH (2006) Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 32:682–685

    PubMed  CAS  Google Scholar 

  36. Gazdar AF, Carbone M (2003) Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 5:177–181

    PubMed  Google Scholar 

  37. Glehen O, Mithieux F, Osinsky D et al (2003) Surgery combined with peritonectomy procedures and intraperitoneal chemohpyerthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 21:799–806

    PubMed  CAS  Google Scholar 

  38. Grégoire M (2010) What’s the place of immunotherapy in malignant mesothelioma treatments? Cell Adhes Migr 4:153–161

    Google Scholar 

  39. Greif J, Marmor S, Merimsky O, Kovner F, Inbar M (1998) Primary liposarcoma of the mediastinum. Sarcoma 2:205–207

    PubMed  CAS  Google Scholar 

  40. Grove CS, Lee YC (2002) Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 8:294–301

    PubMed  Google Scholar 

  41. Guyton AC (1969) Interstitial fluid pressure-volume relationship and their regulation. In Woslsteinholme GEW, Knigh J (eds) Cellular and respiratory mass transport. Ciba Foundation

    Google Scholar 

  42. Hager ED (2006) Intracavitary hyperthermic perfusion. In: Baronzio GF, Hager ED (eds) Hyperthermia in cancer treatment: a primer. Landes bioscience/Springer, New York

    Google Scholar 

  43. Hager ED, Dziambor H, Strama H et al (1996) Intraperitoneal hyperthermic perfusion (IPHP) chemotherapy of patients with peritoneal disseminated drug resistant ovarian cancer. South Med J 89:143

    Google Scholar 

  44. Hager ED, Dziambor H, Höhmann D et al (2001) Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 11:57–63

    PubMed  Google Scholar 

  45. Hahn GM (1979) Potential for therapy of drugs and hyperthermia. Cancer Res 39:2264–2268

    PubMed  CAS  Google Scholar 

  46. Hamilton CA, Maxwell GL, Chernofsky MR et al (2008) Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 11:530–532

    Google Scholar 

  47. Hauck ML, Zalutsky MR (2005) Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: part I: timing of injection relative to hyperthermia. Int J Hyperthermia 21:1–11

    PubMed  CAS  Google Scholar 

  48. Hauck ML, Zalutsky MR (2005) Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: application of the thermal equivalency equation. Int J Hyperthermia 21:13–27

    PubMed  CAS  Google Scholar 

  49. Hauck ML, Dewhirst MW, Bigner DD, Zalutsky MR (1997) Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin Cancer Res 3:63–70

    PubMed  CAS  Google Scholar 

  50. Haveman J, Rietbroek RC, Geerdink A et al (1995) Effect of hyperthermia on the cytotoxicity of 2’, 2’-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 62:627–630

    PubMed  CAS  Google Scholar 

  51. Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127:2209–2221

    PubMed  CAS  Google Scholar 

  52. Hofmann HS, Wiebe K (2010) Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion. Chirurg 81(6):557–562

    PubMed  Google Scholar 

  53. Howell SB (2008) Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int J Gynecol Cancer 18:20–25

    PubMed  Google Scholar 

  54. Howell SB, Zimm S, Markman M et al (1987) Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 5:1607–1612

    PubMed  CAS  Google Scholar 

  55. Hu L, Ferrara N, Jaffe RB (2006) Paracrine VEGF/VE-cadherin action on ovarian cancer permeability. Exp Biol Med (Maywood) 231:1646–1652

    CAS  Google Scholar 

  56. Jaaback K, Johnson N (2006) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 25:CD005340

    Google Scholar 

  57. Jacquet P, Stephens AD, Averbach AM et al (1996) Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 77:1037–1042

    Google Scholar 

  58. Jacquet P, Stuart OA, Chang D, Sugarbaker PH (1996) Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs 7:596–603

    PubMed  CAS  Google Scholar 

  59. Jacquet P, Averbach A, Stuart OA et al (1998) Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 4:147–154

    Google Scholar 

  60. Jakobsen JN, Sørensen JB (2011) Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother Pharmacol 68:1–15

    PubMed  CAS  Google Scholar 

  61. Jantz MA, Antony VB (2008) Pathophysiology of the pleura. Respiration 75:121–133

    PubMed  Google Scholar 

  62. Kobold S, Hegewisch-Becker S, Oechsle K et al (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14:1242–1251

    PubMed  CAS  Google Scholar 

  63. Koga S, Hamazoe R, Maeta M et al (1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232–237

    PubMed  CAS  Google Scholar 

  64. Kraft A, Weindel K, Ochs A et al (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178–87

    PubMed  CAS  Google Scholar 

  65. Lee KA, Harvey JC, Reich H, Beattie EJ (1994) Management of malignant pleural effusions with pleuroperitoneal shunting. J Am Coll Surg 178:586–588

    PubMed  CAS  Google Scholar 

  66. Lerza R, Vannozzi MO, Tolino G (1997) Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Ann Oncol 8:385–391

    PubMed  CAS  Google Scholar 

  67. Leunig M, Goetz AE, Dellian M (1992) Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 52:487–490

    PubMed  CAS  Google Scholar 

  68. Levy AD, Arnáiz J, Shaw JC, Sobin LH (2008) From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics 28:583–607; quiz 621–622

    Google Scholar 

  69. Light RW (2002) Clinical practice. Pleural effusion. N Engl J Med 346(25):1971–1877

    PubMed  Google Scholar 

  70. Light RW (2007) Pleural effusions related to metastatic malignancies. In: Light RW (ed) Pleural diseases. Lippincott Williams & Williams, Philadelphia

    Google Scholar 

  71. Linke R, Klein A, Seimetz D (2010) Catumaxomab: clinical development and future directions. MAbs 2:129–136

    PubMed  Google Scholar 

  72. Loggie BW, Fleming RA, McQuellon RP et al (2000) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 66:561–568

    PubMed  CAS  Google Scholar 

  73. Los G, Mutsaers PH, van der Vijgh WJ (1989) Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380–3384

    PubMed  CAS  Google Scholar 

  74. Lu Z, Wang J, Wientjes MG, Au JL (2010) Intraperitoneal therapy for peritoneal cancer. Future Oncol 6:1625–1641

    PubMed  Google Scholar 

  75. Luh KT, Yang PC, Kuo SH et al (1992) Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer 69:674–679

    PubMed  CAS  Google Scholar 

  76. Lv ZD, Na D, Liu FN et al (2010) Induction of gastric cancer cell adhesion through transforming growth factor-beta1-mediated peritoneal fibrosis. J Exp Clin Cancer Res 29:139

    PubMed  Google Scholar 

  77. Maeda H (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 21:797–802

    PubMed  CAS  Google Scholar 

  78. Maeda S, Sugita M, Sagawa M et al (2011) Fibrous tumor of the pleura suddenly induced hypoglycemia before surgical treatment. Ann Thorac Cardiovasc Surg 17:293–296

    PubMed  Google Scholar 

  79. Markman M (1991) Regional antineoplastic drug delivery in the management of malignant disease. The John Hopkins University Press, Baltimore /London

    Google Scholar 

  80. Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4:277–283

    PubMed  CAS  Google Scholar 

  81. Markman M (2010) Principles of intraperitoneal chemotherapy. In: Alberts DS et al (eds) Intraperitoneal therapy of ovarian cancer. Springer, Berlin/Heidelberg

    Google Scholar 

  82. Matsuzaki Y, Shibata K, Yoshioka M et al (1995) Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion. Ann Thorac Surg 59:127–131

    PubMed  CAS  Google Scholar 

  83. McGuire WP 3rd, Markman M (2003) Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89:S3–8

    PubMed  CAS  Google Scholar 

  84. McQuellon RP, Loggie BW, Fleming RA (2001) Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 27:65–73

    PubMed  CAS  Google Scholar 

  85. Medford AR, Maskell N (2005) Pleural effusion. Postgrad Med J 81:702–710

    PubMed  CAS  Google Scholar 

  86. Meyer PC (1966) Metastatic carcinoma of the pleura. Thorax 2:437–443

    Google Scholar 

  87. Michel CC, Curry FE (1999) Microvascular permeability. Physiol Rev 79:703–761

    PubMed  CAS  Google Scholar 

  88. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592

    PubMed  CAS  Google Scholar 

  89. Miserocchi G (1997) Physiology and pathophysiology of pleural fluid turnover. Eur Respir J 10:219–225

    PubMed  CAS  Google Scholar 

  90. Monjanel-Mouterde S, Frenay C, Catalin J et al (2000) Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions. Oncol Rep 7:171–175

    PubMed  CAS  Google Scholar 

  91. Monneuse O, Beaujard AC, Guibert B et al (2003) Long-term result of intrathoracic chemo hyperthermia (ITCH) for the treatment of pleural malignancies. Br J Cancer 88:1839–1843

    PubMed  CAS  Google Scholar 

  92. Muchmore JH, Wanebo HJ (2008) Regional chemotherapy: overview. Surg Oncol Clin N Am 17:709–730, vii

    PubMed  Google Scholar 

  93. Mujoomdar AA, Sugarbaker DJ (2008) Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 20:298–304

    PubMed  Google Scholar 

  94. Murali R, Park K, Leslie KO (2010) The pleura in health and disease. Semin Respir Crit Care Med 31:649–673

    PubMed  Google Scholar 

  95. Mutaers SE, Wilkosz S (2007) Structure and function of mesothelial cells. In: Ceelen WP (ed) Peritoneal carcinomatosis. A multidisciplinary approach. Springer, New York

    Google Scholar 

  96. Myers CE, Collins JM (1983) Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1:395–407

    PubMed  CAS  Google Scholar 

  97. Nakano T, Chahinian AP, Shinjo M (1999) Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 85:2375–2384

    PubMed  CAS  Google Scholar 

  98. Ninomiya S, Inomata M, Tajima M et al (2009) Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice. J Surg Res 154:196–202

    PubMed  CAS  Google Scholar 

  99. Numnum TM, Rocconi RP, Whitworth J, Barnes MN (2006) The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102:425–428

    PubMed  CAS  Google Scholar 

  100. Ohno S, Siddik ZH, Baba H (1991) Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res 51:2994–3000

    PubMed  CAS  Google Scholar 

  101. Ozols RF, Locker GY, Doroshow JH (1979) Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–3214

    PubMed  CAS  Google Scholar 

  102. Park BJ, Alexander HR, Libutti SK et al (1999) Treatment of primary peritoneal mesotherlioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 6:582–590

    PubMed  CAS  Google Scholar 

  103. Pass HI, Robinson BW, Testa J et al (1999) Emerging translational therapies for mesothelioma. Chest 116:455s–460s

    PubMed  CAS  Google Scholar 

  104. Patriti A, Cavazzoni E, Graziosi L et al (2008) Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech 18:426–428

    PubMed  Google Scholar 

  105. Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH (2001) Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol 47:269–276

    PubMed  CAS  Google Scholar 

  106. Pickhardt PJ, Bhalla S (2005) Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings. Radiographics 25:983–995

    PubMed  Google Scholar 

  107. Pietzner K, Schmuck RB, Fotopoulou C et al (2011) Long term combination treatment with bevacizumab, pegylated liposomal doxorubicin and regional abdominal hyperthermia in platinum refractory ovarian cancer: a case report and review of the literature. Anticancer Res 31:2675–2678

    PubMed  CAS  Google Scholar 

  108. Piver MS, Lele SB, Marchetti DL et al (1988) Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol 6:1679–1684

    PubMed  CAS  Google Scholar 

  109. Price A (2011) What is the role of radiotherapy in malignant pleural mesothelioma? Oncologist 16:359–365

    PubMed  Google Scholar 

  110. Rao W, Deng ZS, Liu J (2010) A review of hyperthermia combined with radiotherapy/chemotherapy on malignant tumors. Crit Rev Biomed Eng 38:101–116

    PubMed  Google Scholar 

  111. Rietbroek RC, van de Vaart PJ, Haveman J (1997) Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 123:6–12

    PubMed  CAS  Google Scholar 

  112. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397–408

    PubMed  CAS  Google Scholar 

  113. Rosso R, Rimoldi R, Salvati F (1988) Intrapleural beta interferon in the treatment of malignant pleural effusions. Oncology 45:253–256

    PubMed  CAS  Google Scholar 

  114. Roviello F, Caruso S, Marrelli D et al (2011) Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol 20:e38–54

    PubMed  Google Scholar 

  115. Rusch VW, Niedzwiecki D, Tao Y et al (1992) Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 10:1001–1006

    PubMed  CAS  Google Scholar 

  116. Saâda E, Follana P, Peyrade F et al (2011) Pathogenesis and management of refractory malignant ascites. Bull Cancer 98:679–687

    PubMed  Google Scholar 

  117. Sadeghi B, Arvieux C, Glehen O et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363

    PubMed  CAS  Google Scholar 

  118. Saif MW, Siddiqui IA, Sohail MA (2009) Management of ascites due to gastrointestinal malignancy. Ann Saudi Med 29:369–377

    PubMed  Google Scholar 

  119. Schmid-Schönbein GW (1999) Biomechanics of microcirculatory blood perfusion. Annu Rev Biomed Eng 1:73–102

    PubMed  Google Scholar 

  120. Schwartz PE, Rutherford TJ, Chambers JT et al (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72:93–99

    PubMed  CAS  Google Scholar 

  121. Sebastian M (2010) Review of catumaxomab in the treatment of malignant ascites. Cancer Manag 2:283–286

    CAS  Google Scholar 

  122. Seimetz D (2011) Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer 2:309–316

    PubMed  CAS  Google Scholar 

  123. Senger DR, Galli SJ, Dvorak AM et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985

    PubMed  CAS  Google Scholar 

  124. Shen P, Levine EA, Hall J et al (2003) Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 138:26–33

    PubMed  CAS  Google Scholar 

  125. Shen P, Stewart JH 4th, Levine EA (2009) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: non-colorectal indications. Curr Probl Cancer 33(3):168–193

    PubMed  Google Scholar 

  126. Shen L, You Y, Sun S (2010) Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posteriorsubtenon application. Ophthalmology 117:2365–2371

    PubMed  Google Scholar 

  127. Shigemura N, Akashi A, Mitsumori O et al (2003) Combined surgery of intrapleural perfusion hyperthermic chemotherapy and panpleuroonectomy for lung cancer with advanced pleural spread: a pilot study. Interact Cardiovasc Thorac Surg 2:671–675

    PubMed  Google Scholar 

  128. Slater NJ, Raftery AT, Cope GH (1989) The ultrastructure of human abdominal mesothelium. J Anat 167:47–56

    PubMed  CAS  Google Scholar 

  129. Sorokin SP (1988) The respiratory system. In: Weiss L (ed) Cell and tissue biology. Urban & Schwarzenberg, Munich

    Google Scholar 

  130. Spratt JS, Adcock RA, Muskovin M et al (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256–260

    PubMed  CAS  Google Scholar 

  131. Spratt JS, Adcock RA, Sherrill W, Travathen S (1980) Hyperthermic peritoneal perfusion system in canines. Cancer Res 40:253–255

    PubMed  CAS  Google Scholar 

  132. Sugarbacker DJ, Jacklitsch MT, Soutter AD et al (1996) Multimodality therapy of malignant mesothelioma. In: Roth JA, Ruckdeschel JC, Weisenburger TH (eds) Thoracic oncology, 2nd edn. WB Saunders Co, Philadelphia

    Google Scholar 

  133. Sugarbaker PH (1996) Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Cancer Treat Res 82:317–325

    PubMed  CAS  Google Scholar 

  134. Sugarbaker PH (2007) Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia 23:431–442

    PubMed  CAS  Google Scholar 

  135. Sugarbaker PH, Gianola FJ, Speyer JL et al (1995) Prospective randomized trial of intravenous vs. intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol 12:101–111

    Google Scholar 

  136. Sugarbaker PH, Van der Speeten K, Stuart OA (2010) Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol 2:19–30

    PubMed  Google Scholar 

  137. Tamsma JT, Keizer HJ, Meinders AE (2001) Pathogenesis of malignant ascites: Starling’s law of capillary hemodynamics revisited. Ann Oncol 10:1353–1357

    Google Scholar 

  138. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC (1981) Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 41:1096–1099

    PubMed  CAS  Google Scholar 

  139. Thickett DR, Armstrong L, Millar AB (1999) Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 54(8):707–710

    PubMed  CAS  Google Scholar 

  140. Trinh XB, Tjalma WA, Vermeulen PB et al (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 100(6):971–978

    PubMed  CAS  Google Scholar 

  141. Triviño A, Cozar F, Congregado M, Loscertales J (2011) Giant solitary fibrous tumor of the pleura. Interact Cardiovasc Thorac Surg 12:1063–1065

    PubMed  Google Scholar 

  142. Uzbeck MH, Almeida FA, Sarkiss MG (2010) Management of malignant pleural effusions. Adv Ther 27:334–347

    PubMed  Google Scholar 

  143. Valle M, Van der Speeten K, Garofalo A (2009) Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol 100:331–334

    PubMed  CAS  Google Scholar 

  144. van Thiel E, van Meerbeeck JP (2010) European guidelines for the management of malignant pleural mesothelioma. Pol Arch Med Wewn 120:503–510

    PubMed  Google Scholar 

  145. Verheul HM, Hoekman K, Jorna AS et al (2000) Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 5:45–50

    PubMed  CAS  Google Scholar 

  146. Wiener-Kronish JP, Broaddus VC (1993) Interrelationship of pleural and pulmonary interstitial liquid. Ann Rev Physiol 55:209–226

    CAS  Google Scholar 

  147. Yanagawa H, Takeuchi E, Suzuki Y et al (1999) Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 48:396–400

    PubMed  CAS  Google Scholar 

  148. Yano S, Herbst RS, Shinohara H et al (2000) Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 6:957–965

    PubMed  CAS  Google Scholar 

  149. Yellin A, Simansky D, Paley M et al (2002) Surgery and hyperthermic pleural perfusion, a new approach for malignancies with pleural involvement. Harefuah 141:335–339, 411

    PubMed  Google Scholar 

  150. Zakris EL, Dewhirst MW, Riviere JE et al (1987) Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 5:1613–1620

    PubMed  CAS  Google Scholar 

  151. Zebrowski BK, Liu W, Ramirez K et al (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6:373–378

    PubMed  CAS  Google Scholar 

  152. Zeimet AG, Reimer D, Radl AC et al (2009) Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res 29:2803–2808

    PubMed  CAS  Google Scholar 

  153. Zoetmulder FA, van der Vange N, Witkamp AJ et al (1999) Hyperthermia intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands cancer institute. Ned Tijdschr Geneesk 143:1863–1868

    CAS  Google Scholar 

  154. Zweifach BW (1973) Microcirculation. Annu Rev Physiol 35:117–150

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro Medico Kines, Via San Gerolamo 29, 20022, Castano Primo, Mi, Italy

    Gianfranco Baronzio

  2. Oncology Unit, Azienda Ospedaliera Marche Nord ‘San Salvatore’ di Pesaro, Pesaro, Italy

    Giammaria Fiorentini

  3. Centro Demetra, Terni, Italy

    Marco Ballerini & Valter Cassuti

  4. Gynecolic Oncology Unit, Hospital of Gallarate, Gallarate, VA, Italy

    Giorgio Forzenigo

  5. RanD Biotech, Medolla, MO, Italy

    Eugenio Morsiani

Authors
  1. Gianfranco Baronzio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giammaria Fiorentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Ballerini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valter Cassuti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giorgio Forzenigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eugenio Morsiani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gianfranco Baronzio .

Editor information

Editors and Affiliations

  1. Research Center RAMS, Laboratory of Cell Immunity, N.N. Blokhin Russian Cancer, Kashirskoye sh. 24, Moscow, 115478, Russia

    Mikhail V. Kiselevsky

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Baronzio, G., Fiorentini, G., Ballerini, M., Cassuti, V., Forzenigo, G., Morsiani, E. (2012). Hyperthermia and Intracavitary Chemotherapy in Prevention and Treatment of Malignant Effusions. In: Kiselevsky, M. (eds) Malignant Effusions. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4783-8_7

Download citation

Publish with us

Policies and ethics

Search

Navigation